Quantcast

Supernus Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold


Shutterstock photo

Supernus Pharmaceuticals ( SUPN ) had its Relative Strength ( RS ) Rating upgraded from 74 to 81 Wednesday.

[ibd-display-video id=2881825 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.

Decades of market research reveals that the best stocks tend to have an RS Rating of at least 80 in the early stages of their moves.

Looking For The Best Stocks To Buy And Watch? Start Here

Supernus Pharmaceuticals is working on a consolidation with a 50.14 entry . See if the stock can break out in volume at least 40% above average.

The company posted -28% earnings growth last quarter, while sales growth came in at 42%.

Supernus Pharmaceuticals earns the No. 35 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics ( CORT ), Vertex Pharmaceuticals ( VRTX ) and Ligand Pharmaceuticals ( LGND ) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Rising Relative Strength?

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Stocks
Referenced Symbols: SUPN , RS , CORT , VRTX , LGND


More from Investor's Business Daily

Subscribe






Investor's Business Daily
Contributor:

Investor's Business Daily

Investing








Research Brokers before you trade

Want to trade FX?